stoxline Quote Chart Rank Option Currency Glossary
Crinetics Pharmaceuticals, Inc. (CRNX)
33.48  0.25 (0.75%)    12-07 16:00
Open: 33.23
High: 33.645
Volume: 484,072
Pre. Close: 33.23
Low: 32.82
Market Cap: 2,236(M)
Technical analysis
2023-12-07 4:19:52 PM
Short term     
Mid term     
Targets 6-month :  39.81 1-year :  46.5
Resists First :  34.09 Second :  39.81
Pivot price 31.63
Supports First :  28.93 Second :  25.75
MAs MA(5) :  33.27 MA(20) :  30.69
MA(100) :  24.92 MA(250) :  21.35
MACD MACD :  1.2 Signal :  1
%K %D K(14,3) :  90.6 D(3) :  92.2
RSI RSI(14): 66.6
52-week High :  34.09 Low :  15.22
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ CRNX ] has closed below upper band by 19.1%. Bollinger Bands are 4.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 34.11 - 34.28 34.28 - 34.42
Low: 32.69 - 32.87 32.87 - 33.01
Close: 32.94 - 33.25 33.25 - 33.48
Company Description

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Headline News

Thu, 07 Dec 2023
Can Crinetics Pharmaceuticals Inc (CRNX) Stock Rise to the Top of Healthcare Sector Thursday? - InvestorsObserver

Tue, 05 Dec 2023
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Short Interest Down 7.6% in November - MarketBeat

Wed, 29 Nov 2023
Crinetics Pharmaceuticals Inc (CRNX) is up 5.88% in a Week, Should You Buy? - InvestorsObserver

Tue, 28 Nov 2023
Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans - Simply Wall St

Mon, 27 Nov 2023
Will Crinetics Pharmaceuticals Inc (CRNX) Beat the Rest of the Stocks in the Healthcare Sector? - InvestorsObserver

Mon, 20 Nov 2023
Is Crinetics Pharmaceuticals Inc (CRNX) a Smart Choice in Biotechnology Monday? - InvestorsObserver

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 67 (M)
Held by Insiders 6.119e+007 (%)
Held by Institutions 2.4 (%)
Shares Short 6,810 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -2.0639e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -17 %
Return on Assets (ttm) 45.3 %
Return on Equity (ttm) -25.3 %
Qtrly Rev. Growth 4.72e+006 %
Gross Profit (p.s.) -43.75
Sales Per Share -79.22
EBITDA (p.s.) -2.24089e+008
Qtrly Earnings Growth -3.7 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -163 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.43
Price to Cash Flow 2.28
Stock Dividends
Dividend 0
Forward Dividend 6.2e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android